Shanshan Dai

Shanshan Dai

Auto-generated profile, based on publicly available information

Shanshan Dai

Department of Emergency, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Emergency and Disaster Medicine of Wenzhou, Wenzhou, Zhejiang, 325000, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
SDShanshan Dai
Shanshan Dai
BYBozhi Ye
Bozhi Ye
LCLongwang Chen
Longwang Chen
GHGuangliang Hong
Guangliang Hong
GZGuang-ju Zhao
Guang-ju Zhao
ZLZhonqiu Lu
Zhonqiu Lu

2 October 2023 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
LZLingfeng Zhong
Lingfeng Zhong
JHJibo Han
Jibo Han
XFXiaoxi Fan
Xiaoxi Fan
ZHZhouqing Huang
Zhouqing Huang
LSLan Su
Lan Su
BYBozhi Ye
Bozhi Ye

8 April 2024 in Redox Biology
Verified
Journal Article
Open access
XZXin Zhong
Xin Zhong
KWKangwei Wang
Kangwei Wang
YWYonghua Wang
Yonghua Wang
LWLuya Wang
Luya Wang
SWSudan Wang
Sudan Wang
ZHZhouqing Huang
Zhouqing Huang
Continuous remodeling of the heart can result in adverse events such as reduced myocardial function and heart failure. Available evidence indicates that ferroptosis is a key process in the emergence of cardiac disease. P2 family purinergic receptor P2X7 receptor (P2X7R) activation plays a crucial role in numerous aspects of cardiovascular disease. The aim of this study was to elucidate any potential interactions between P2X7R and ferroptosis in cardiac remodeling stimulated by angiotensin II (Ang II), and P2X7R knockout mice were utilized to explore the role of P2X7R and elucidate its underlying mechanism through molecular biological methods. Ferroptosis is involved in cardiac remodeling, and P2X7R deficiency significantly alleviates cardiac dysfunction, remodeling, and ferroptosis induced by Ang II. Mechanistically, Ang II interacts with P2X7R directly, and LYS-66 and MET-212 in the in the ATP binding pocket form a binding complex with Ang II. P2X7R blockade influences HuR-targeted GPX4 and HO-1 mRNA stability by affecting the shuttling of HuR from the nucleus to the cytoplasm and its expression. These results suggest that focusing on P2X7R could be a possible therapeutic approach for the management of hypertensive heart failure.

24 December 2024 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
BYBozhi Ye
Bozhi Ye
XCXueli Cai
Xueli Cai
XLXiaohe Liang
Xiaohe Liang
YCYunxuan Chen
Yunxuan Chen
SDShanshan Dai
Shanshan Dai
ZJZhuyin Jia
Zhuyin Jia

14 March 2022 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
SLShuang Lin
Shuang Lin
SDShanshan Dai
Shanshan Dai
JLJiahui Lin
Jiahui Lin
XLXiaohe Liang
Xiaohe Liang
WWWeiqi Wang
Weiqi Wang
XHXia Hong
Xia Hong
Myocardial remodeling is one of the main lesions in the late stage of chronic heart failure and seriously affects the prognosis of patients. Continuous activation of the renin-angiotensin-aldosterone system (RAAS) contributes to the development of myocardial remodeling greatly, and angiotensin II (Ang II), its main constituent, can directly lead to cardiac remodeling through an inflammatory response and oxidative stress. Since Ang II-induced myocardial remodeling is closely related to inflammation, we tried to explore whether the anti-inflammatory drug oridonin (Ori) can reverse this process and its possible mechanism. Our study investigated that hypertrophy and fibrosis can be induced after being treated with Ang II in cardiomyocytes (H9c2 cells and primary rat cardiomyocytes) and C57BL/6J mice. The anti-inflammatory drug oridonin could effectively attenuate the degree of cardiac remodeling both in vivo and vitro by inhibiting GSDMD, a key protein of intracellular inflammation which can further activate kinds of inflammation factors such as IL-1β and IL-18. We illustrated that oridonin reversed cardiac remodeling by inhibiting the process of inflammatory signaling through GSDMD. After inhibiting the expression of GSDMD in cardiomyocytes by siRNA, it was found that Ang II-induced hypertrophy was attenuated. These results suggest that oridonin is proved to be a potential protective drug against GSDMD-mediated inflammation and myocardial remodeling.

26 July 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SSSi Shi
Si Shi
RZRuihan Zheng
Ruihan Zheng
LLLi Luo
Li Luo
BXBinbin Xia
Binbin Xia
ZYZexin Yang
Zexin Yang
SDShanshan Dai
Shanshan Dai